Research ArticleResearch Article

Association between HER-2 Over-Expression and Prognosis in Human Osteosarcoma: a Meta-Analysis

Yueguo Li and Ning Zhang
Chinese Journal of Clinical Oncology October 2008, 5 (5) 367-372; DOI: https://doi.org/10.1007/s11805-008-0367-x

Article Figures & Data

Figures

  • Fig.1.
    Fig.1. SROC curve analysis summarizing the discriminating ability of HER-2 status for separating good and poor responders to chemotherapy based on histologic criteria (as defined in “Materials and Methods”).

    Each study is shown by a circle demonstrating the sensitivity and specificity of HER-2 status for predicating a poor histologic response. The data are summarized with weighted and unweighted SROC.

  • Fig.2.
    Fig.2. Meta-analysis of the association between HER2 status and the risk of death at 2 years.

    Each study is shown by the name of the lead author, and the relative risk with 95% confidence intervals. Also shown are the summary relative risk (total) and 95% confidence intervals with random effect calculations.

Tables

  • Table 1.

    Characteristics of eligible studies.

    Authors (y)No. AnalyzedMetastatic diseaseAge, yearsM or C Staining*IHC AntibodyIHC cut-off (%)Positive (%)Chemotherapy response (criteria)Deaths in 2 years
    Gorlick (1999)531016.6M5B5254518/53 (Huvos)16/53
    Scott E (2001)411429CCB1110 (3+)6023/41 (N90)3/25
    Carol D (2001)53618M3B5254518/53 (Huvos)16/53
    Akatauka (2002)81NR20MCB11306238/81 (N90)14/81
    Zhou (2003)25614MAb325449/19 (N90)12/25
    Scottlandi (2005)84NR23M3b52532NR30/84

    • ↵* Membranous or cytoplasmic Staining; IHC, immunohistochemistry; NR, not reported; N90, histologic response based on > 90% tumor cell necrosis.

  • Table 2.

    Likelihood ratios for the association between HER-2 status and no histologic response to chemotherapy.

    StudiesN (n)Positive LR (95% CI)QNegative LR (95% CI)Q
    All6 (247)1.27 (0.91-1.77)8.780.68 (0.38-1.22)11.13
    14 (206)1.34 (0.92-1.95)7.830.56 (0.25-1.26)9.83
    23 (125)1.62 (1.24-2.11)0.020.37 (0.20-0.68)0.23

    • All figures are based on random effects calculation. All P values for between-study heterogneity were > 0.05. Abbreviations: 1, studies scoring for membranous staining; 2, studies using the 25% IHC cutoff.

  • Table 3.

    Relative risk for association between HER2 status and mortality in 2 years.

    StudiesN (n)QRelative risk (95% CI)
    All6 (321)15.691.78 (0.90-3.48)1
    Scoring for membranous staining only5 (296)14.201.93 (0.96-3.87)2
    25% IHC cutoff only4 (215)1.412.81 (1.91-4.13)3

    • ↵1 P values were < 0.05 for between-study heterogeneity, relative risk was estimated with random effects models.

    • ↵2 P values were < 0.05 for between-study heterogeneity, relative risk was estimated with random effects models.

    • ↵3 P values were >0.05 for between-study heterogeneity, Relative risk was estimated with fixed effects models. Abbreviations: CI, confidence intervals.

Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords